The ability of in silico methodologies to provide epochal benefits to both regulatory requirements and the pharmaceutical sector to analyse the safety profile has been made possible by advancements in computational research.Piracetam is the first nootropic drug to be widely used in medicine, and its success can be linked to cyclic gamma-aminobutyric acid derivatives. Schrodinger Maestro (v11.1) software was used to conduct a molecular docking investigation of suggested derivatives with protein obtained from protein data bank.A possible route for the creation of brand-new neuroprotective medications is the manufacture of piracetam compounds with significant nootropic action.The purpose of the study is to carry out molecular docking studies to predict the GABA-ergic and glutamatergic activities of N-acyl derivatives of 2-(2-oxopyrolidin-1-yl)-acetamide by analysing the energy of interactions between modelled structures and GABAA and AMPA receptors, followed by targeted synthesis.Out of total 40 only 20 derivatives was found to active because of suitable interaction with the receptor and are the potential candidates for peripheral neuropathy.